Sugammadex 200 & 500 Drl 200 mg, 500 mg Solution for injection
PDF Leaflet Revision Date: 29 August 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Routine and immediate reversal of neuromuscular blockade induced by rocuronium or vecuronium.
Dosage (summary)
4 mg/kg for profound blockade, 2 mg/kg for shallow blockade, 16 mg/kg for immediate reversal.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
- Obese patients
- Paediatric patients
Pregnancy & Breastfeeding
Safety in pregnancy not established; excretion in breast milk expected.
Key Drug Interactions
- Toremifene
- Fusidic acid
- Hormonal contraceptives
Contraindications
- Hypersensitivity to sugammadex or excipients
- Use with depolarising neuromuscular blockers
Common side effects
- Cough
- Airway complications
- Hypotension
- Dysgeusia
Counselling Points
- Monitor respiratory function post-administration
- Inform about potential hypersensitivity reactions
- Advise on contraceptive measures if applicable
Serious warnings
- Monitor for recurrence of neuromuscular blockade
- Marked bradycardia observed
- Caution in patients with coagulopathy
Important Disclaimer
The Sugammadex 200 & 500 Drl 200 mg, 500 mg Solution for injection professional information leaflet below is the property of Lnnovata Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
